

<b>National Imaging Associates, Inc.*</b>	
<b>Clinical guidelines HEART (Cardiac) PET</b>	<b>Original Date: July 1999</b>
<b>CPT Codes: 78459, 78491, 78492, +78434</b>	<b>Last Revised Date: March 2021</b>
<b>Guideline Number: NIA_CG_072</b>	<b>Implementation Date: January 2022</b>

## GENERAL INFORMATION

It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. All prior relevant imaging results<sup>1</sup> and the reason that alternative imaging cannot be performed must be included in the documentation submitted.

## INDICATIONS FOR HEART PET

### SUSPECTED CAD (When neither SE nor MPI have provided or are expected to provide optimal imaging)

#### Symptomatic patients without known CAD (use [Diamond Forrester Table](#))

- Low or intermediate pretest probability and unable to exercise
- High pretest probability
- Repeat testing in a patient with new or worsening symptoms and negative result at least one year ago **AND** meets one of the criteria above

#### Asymptomatic patients without known CAD

- Previously unevaluated ECG evidence of possible myocardial ischemia including substantial ischemic ST segment or T wave abnormalities
- Previously unevaluated pathologic Q waves
- Unevaluated complete left bundle branch block
- —History of diabetes mellitus, > 40 years old, with calcium score >400
- —

\* National Imaging Associates, Inc. (NIA) is a subsidiary of Magellan Healthcare, Inc.

**INCONCLUSIVE CAD EVALUATION WITHIN THE PAST 2 YEARS AND OBSTRUCTIVE CAD REMAINS A CONCERN (When neither SE nor MPI have provided or are expected to provide optimal imaging)**

- Exercise stress ECG with low risk Duke treadmill score ( $\geq 5$ ), but patient's current symptoms indicate an intermediate or high pretest probability
- Exercise stress ECG with an intermediate Duke treadmill score
- Inconclusive/borderline coronary computed tomography angiography (CCTA) (e.g., 40 - 70% lesions)
- Non-diagnostic exercise stress test with physical inability to achieve target heart rate (THR)
- An intermediate evaluation by prior stress imaging (within the past 2 years)

**FOLLOW-UP OF PATIENT'S POST CORONARY REVASCULARIZATION (PCI or CABG) ~~when~~ when LVEF is  $\leq 40\%$  and revascularization is under consideration**

- **Asymptomatic, follow-up stress imaging** at a minimum of 2 years post coronary artery bypass grafting (CABG), or percutaneous coronary intervention (PCI), (whichever is later), is appropriate only for patients with a history of silent ischemia, or a history of a prior left main stent  
**OR**
- For patients with high occupational risk (e.g., associated with public safety, airline and boat pilots, bus and train drivers, bridge and tunnel workers/toll collectors, police officers, and firefighters)
- **New, recurrent, or worsening symptoms post coronary revascularization**, is an indication for stress imaging, if it will alter management

**FOLLOW-UP OF KNOWN CAD (When neither SE nor MPI have provided or are expected to provide optimal imaging)**

- For assessment of suspected significant hibernating myocardium in the presence of known severe major vessel CAD, when EF is below 40%, in order to determine a patient's potential benefit from coronary revascularization (Patel, 2013; Tsai, 2014; Yancy, 2013)
- **Routine follow-up of asymptomatic or stable symptoms** when last invasive or non-invasive assessment of coronary disease showed hemodynamically significant CAD (ischemia on stress test or  $\text{FFR} \leq 0.80$  or stenosis greater than or equal to 70% of a major vessel), over two years ago, without intervening coronary revascularization is an appropriate indication for stress imaging in patients if it will alter management

**SPECIAL DIAGNOSTIC CONDITIONS REQUIRING CORONARY EVALUATION (When neither SE nor MPI have provided or are expected to provide optimal imaging)**

- Prior acute coronary syndrome (as documented in MD notes), without subsequent invasive or non-invasive coronary evaluation
- Newly diagnosed systolic heart failure (EF < 50%), especially with symptoms or signs of ischemia unless invasive coronary angiography is immediately planned (Fihn, 2012; Patel, 2013; Yancy, 2013)
- Reduced LVEF ≤ 50% requiring myocardial viability assessment to assist with decisions regarding coronary revascularization. (Diversion from PET not required when LVEF less than or equal to 40%) (Patel, 2013; Tsai, 2014; Yancy, 2013)
- Ventricular arrhythmias
  - Sustained ventricular tachycardia (VT) > 100 bpm, ventricular fibrillation (VF), or exercise-induced VT, when invasive coronary arteriography is not the immediately planned test (Al-Khatib, 2018)
  - Nonsustained VT, multiple episodes, each ≥ 3 beats at ≥ 100 bpm, frequent PVC's (defined as greater than or equal to 30/hour on remote monitoring) without known cause or associated cardiac pathology, when an exercise ECG cannot be performed
- Prior to Class IC antiarrhythmic drug initiation (Propafenone or Flecainide), as well as annually in intermediate and high global risk patients (SE diversion not required) (Reiffel, 2015)
- Assessment of hemodynamic significance of one of the following documented conditions (Anagnostopoulos, 2004):
  - Anomalous coronary arteries (Grani, 2017)
  - Muscle bridging of coronary artery (perform with exercise stress) (Sorajja, 2021)
- Coronary aneurysms in Kawasaki's disease (McCrindle, 2017) or due to atherosclerosis
- Following radiation therapy to the anterior or left chest, at 5 years post initiation and every 5 years thereafter (Lancellotti, 2013)
- **Cardiac Sarcoidosis** (Birnie, 2016; Blankstein, 2016; Vita, 2018)
  - Evaluation and therapy monitoring in patients with sarcoidosis, after documentation of suspected cardiac involvement by echo or ECG, when CMR has not been performed
  - Evaluation of suspected cardiac sarcoid, after CMR has shown equivocal or negative findings in the setting of a high clinical suspicion (Vita, 2018)
  - Evaluation of CMR findings showing highly probable cardiac sarcoidosis, when PET could serve to identify inflammation and the consequent potential role for immunosuppressive therapy (Vita, 2018)
  - Initial and follow-up PET in monitoring therapy for cardiac sarcoid with immunosuppressive therapy, typically about 4 times over 2 years
- **Infective Endocarditis**

- In suspected infective endocarditis with moderate to high probability (i.e., staph bacteremia, fungemia, prosthetic heart valve, or intracardiac device), when TTE and TEE have been inconclusive with respect to diagnosis of infective endocarditis or characterization of paravalvular invasive complications (Doherty, 2017; Habib, 2016; Wang, 2018)
- **Aortitis**
  - For diagnosis and surveillance of Aortitis, PET/CT or PET/MRI<sup>‡</sup> hybrid imaging (Bhave, 2018)
  - <sup>‡</sup>NOTE: If PET/MR study is requested, there is no specific CPT Code for this imaging study and a Health Plan review will be required.

**PRIOR TO ELECTIVE NON-CARDIAC SURGERY (When neither SE nor MPI have provided or are expected to provide optimal imaging)**

- Patients who have no other indication for a non-invasive coronary evaluation, but are referred for preoperative cardiac evaluation, are eligible for MPI if **all 4 criteria** are met:
  - Surgery is supra-inguinal vascular, intrathoracic, or intra-abdominal;<sup>‡</sup>
  - AND**
  - The patient has **at least one** of the additional cardiac complication risk factors:
    - Ischemic Heart Disease
    - History of stroke or TIA
    - History of congestive heart failure or ejection fraction  $\leq 35\%$
    - Insulin-requiring diabetes mellitus
    - Creatinine  $\geq 2.0$  mg/dl
  - AND**
  - The patient has limited functional capacity ( $< 4$  METS), such as one of the following:
    - Unable to take care of their activities of daily living (ADLs) or ambulate
    - Unable to walk 2 blocks on level ground
    - Unable to climb 1 flight of stairs
  - AND**
  - There has not been a conclusive stress evaluation, CTA, or heart catheterization within the past year, and the results of such a test would be likely to substantially alter therapy and/or preclude proceeding with the intended surgery.
- Planning for solid organ transplantation is an indication for preoperative MPI, if there has not been a conclusive stress evaluation, CTA, or heart catheterization within the past year with  $\geq 3$  of the following risk factors (SE diversion not required) (Lentine, 2012):
  - Age  $> 60$
  - Smoking

- Hypertension
- Dyslipidemia
- Left ventricular hypertrophy
- 1 year on dialysis (for renal transplant patients)
- Diabetes mellitus
- Prior ischemic heart disease

## POST CARDIAC TRANSPLANT (SE diversion not required)

(McArdle, 2012)

- ~~Annually~~, for the first five years post cardiac transplantation, in a patient not undergoing invasive coronary arteriography
- After the first five years post cardiac transplantation, patients with documented transplant coronary vasculopathy can be screened annually if invasive coronary arteriography is not planned

## BACKGROUND

(Bateman, 2016; Fazel, 2011)

### PET Scan

- ~~PET is indicated when all the criteria for MPI are met~~
- **AND** ~~there is likely to be equivocal imaging results because of BMI or large breasts or implants or prior thoracic surgery or results of a prior MPI~~
- ~~For assessment of suspected significant hibernating myocardium in the presence of known severe major vessel CAD, when EF is below 40%, in order to determine a patient's potential benefit from coronary revascularization (Patel, 2013; Tsai, 2014; Yancy, 2013)~~
- ~~When strong suspicion of balanced ischemia is noted, and further non-invasive coronary evaluation required, PET can be used, without diversion from PET (Bengel, 2009)~~
- ~~Prior alternative perfusion (MPI or CMR) imaging resulted in an indeterminate evaluation for CAD~~
- ~~Cardiac positron emission tomography (PET) can characterize myocardial blood flow by perfusion scanning with either rubidium-82 (Rb-82) or nitrogen-13 (N-13) ammonia~~
- **CPET** can identify regions of myocardial viability with hibernating myocardium (viable, with poor flow and contractility) by imaging with fluorine-18 (F-18) fluorodeoxyglucose (FDG or 18-FDG) for this purpose.
- ~~UPET can be use~~ useful in the evaluation of inflammation: e.g., evaluation and therapy monitoring in patients with sarcoidosis, after documentation of cardiac involvement by echo or electrocardiography (ECG), in place of, or subsequent to CMR if needed to help with an uncertain diagnosis

**Coronary application of PET** includes evaluation of **stable patients without known CAD**, who fall into two categories (Fihn, 2012; Montalescot, 2013; Wolk, 2014)

- **Asymptomatic**, for whom global risk of CAD events can be determined from coronary risk factors, using calculators available online (see Websites for [Global Cardiovascular Risk Calculators](#) section).
- **Symptomatic**, for whom we estimate the pretest probability that their chest-related symptoms are due to clinically significant ( $\geq 50\%$ ) CAD (below):

### The 3 Types of Chest Pain or Discomfort

- **Typical Angina (Definite)** is defined as including all **3** characteristics:
  - Substernal chest pain or discomfort with characteristic quality and duration
  - Provoked by exertion or emotional stress
  - Relieved by rest and/or nitroglycerine
- **Atypical Angina (Probable)** has only **2** of the above characteristics
- **Nonanginal Chest Pain/Discomfort** has only **0 - 1** of the above characteristics

Once the type of chest pain has been established from the medical record, the Pretest Probability of CAD (meaning obstructive CAD defined as coronary arterial narrowing  $\geq 50\%$ ) is estimated from the **Diamond Forrester Table** below, recognizing that in some cases multiple additional coronary risk factors could increase pretest probability (Fihn, 2012; Wolk, 2014<sup>43</sup>):

#### Diamond Forrester Table

Age (Years)	Gender	Typical/Definite Angina Pectoris	Atypical/Probable Angina Pectoris	Nonanginal Chest Pain
$\leq 39$	Men	Intermediate	Intermediate	Low
	Women	Intermediate	Very low	Very low
40 – 49	Men	High	Intermediate	Intermediate
	Women	Intermediate	Low	Very low
50 – 59	Men	High	Intermediate	Intermediate
	Women	Intermediate	Intermediate	Low
$\geq 60$	Men	High	Intermediate	Intermediate
	Women	High	Intermediate	Intermediate

- Very Low:  $< 5\%$  pretest probability, usually not requiring stress evaluation
- **Low:** 5 - 10% pretest probability of CAD
- **Intermediate:** 10% - 90% pretest probability of CAD
- **High:**  $> 90\%$  pretest probability of CAD

## OVERVIEW

### ECG Stress Test Alone versus Stress Testing with Imaging

Prominent scenarios suitable for an ECG stress test WITHOUT imaging (i.e., exercise treadmill ECG test) require that the patient can exercise for at least 3 minutes of Bruce protocol with achievement of near maximal heart rate AND has an interpretable ECG for ischemia during exercise (Wolk, 2014):

- The (symptomatic) low or intermediate pretest probability patient who is able to exercise and has an interpretable ECG (Wolk, 2014)
- The patient who is under evaluation for exercise-induced arrhythmia
- The patient who requires an entrance stress test ECG for a cardiac rehab program or for an exercise prescription
- For the evaluation of syncope or presyncope during exertion (Shen, 2017)

### Duke Exercise ECG Treadmill Score (Mark, 1987)

Calculates risk from ECG treadmill alone:

- The equation for calculating the Duke treadmill score (DTS) is:  $DTS = \text{exercise time in minutes} - (5 \times \text{ST deviation in mm or } 0.1 \text{ mV increments}) - (4 \times \text{exercise angina score})$ , with angina score being 0 = none, 1 = non-limiting, and 2 = exercise-limiting.
- The score typically ranges from - 25 to + 15. These values correspond to low-risk (with a score of  $\geq + 5$ ), intermediate risk (with scores ranging from - 10 to + 4), and high-risk (with a score of  $\leq - 11$ ) categories.

An uninterpretable baseline ECG includes (Fihn, 2012):

- ST segment depression 1 mm or more (not for non-specific ST- T wave changes)
- Ischemic looking T waves; at least 2.5 mm inversions (excluding V1 and V2)
- LVH with repolarization abnormalities, pre-excitation pattern such as WPW, ventricular paced rhythm, or left bundle branch block
- Digitalis use with associated ST segment abnormalities

## Global Risk of Cardiovascular Disease

**Global risk** of CAD is defined as the probability of manifesting cardiovascular disease over the next 10 years and refers to **asymptomatic** patients without known cardiovascular disease. It should be determined using one of the risk calculators below. A high risk is considered greater than a 20% risk of a cardiovascular event over the ensuing 10 years. **High global risk by itself generally lacks scientific support as an indication for stress imaging.** There are rare exceptions, such as patients requiring IC antiarrhythmic drugs who might require coronary risk stratification prior to initiation of the drug or patients with a CAC score > 400 Agatston units, when global risk is moderate or high.

- **CAD Risk—Low**  
10-year absolute coronary or cardiovascular risk less than 10%.

- **CAD Risk—Moderate**  
10-year absolute coronary or cardiovascular risk between 10% and 20%.
- **CAD Risk—High**  
10-year absolute coronary or cardiovascular risk of greater than 20%.



## Websites for Global Cardiovascular Risk Calculators\*

(Arnett, 2019; D'Agostino, 2008; Goff, 2014; McClelland, 2015; Ridker, 2007)

\*Patients who have already manifested cardiovascular disease are already at high global risk and are not applicable to the calculators.

Risk Calculator	Websites for Online Calculator
Framingham Cardiovascular Risk	<a href="https://reference.medscape.com/calculator/framingham-cardiovascular-disease-risk">https://reference.medscape.com/calculator/framingham-cardiovascular-disease-risk</a>
Reynolds Risk Score Can use if no diabetes Unique for use of family history	<a href="http://www.reynoldsriskscore.org/">http://www.reynoldsriskscore.org/</a>
Pooled Cohort Equation	<a href="http://clincalc.com/Cardiology/ASCVD/PooledCohort.aspx?example">http://clincalc.com/Cardiology/ASCVD/PooledCohort.aspx?example</a>
ACC/AHA Risk Calculator	<a href="http://tools.acc.org/ASCVD-Risk-Estimator/">http://tools.acc.org/ASCVD-Risk-Estimator/</a>
MESA Risk Calculator With addition of Coronary Artery Calcium Score, for CAD-only risk	<a href="https://www.mesa-nhlbi.org/MESACHDRisk/MesaRiskScore/RiskScore.aspx">https://www.mesa-nhlbi.org/MESACHDRisk/MesaRiskScore/RiskScore.aspx</a>

## Definitions of Coronary Artery Disease

(Fihn, 2012; Montalescot, 2013; Patel, 2017)

Percentage stenosis refers to the reduction in diameter stenosis when angiography is the method and can be estimated or measured using angiography or more accurately measured with intravascular ultrasound (IVUS).

- Coronary artery calcification is a marker of risk, as measured by Agatston score on coronary artery calcium imaging. It is not a diagnostic tool so much as it is a **risk stratification** tool. Its incorporation into global risk can be achieved by using the MESA risk calculator.
- Ischemia-producing disease (also called hemodynamically or functionally significant disease, for which revascularization might be appropriate) generally implies at least one of the following:

- Suggested by percentage diameter stenosis  $\geq 70\%$  by angiography; borderline lesions are 40 - 70% (Fihn, 2012)
- For a left main artery, suggested by a percentage stenosis  $\geq 50\%$  or minimum lumen cross-sectional area on IVUS  $\leq 6$  square mm (Fihn, 2012; Lofti, 2018)
- FFR (fractional flow reserve)  $\leq 0.80$  for a major vessel (Lofti, 2018)
- iFR (instantaneous wave-free ratio)  $\leq 0.89$  for a major vessel (Davies, 2017; Gotberg, 2017; Lofti, 2018)
- Demonstrable ischemic findings on stress testing (ECG or stress imaging), that are at least mild in degree
- A major vessel would be a coronary vessel that would be amenable to revascularization if indicated. This assessment is made based on the diameter of the vessel and/or the extent of myocardial territory served by the vessel.
- FFR (fractional flow reserve) is the distal to proximal pressure ratio across a coronary lesion during maximal hyperemia induced by either intravenous or intracoronary adenosine. Less than or equal to 0.80 is considered a significant reduction in coronary flow.
- iFR (instantaneous wave-free ratio) measures the ratio of distal coronary to aortic pressure during the wave free period of diastole, with a value  $\leq 0.89$  considered hemodynamically significant (Davies, 2017; Gotberg, 2017).
- Newer technology that estimates FFR from CCTA image is covered under the separate NIA Guideline for FFR-CT.

### Anginal Equivalent

(Fihn, 2012; Shen, 2017)

Development of an anginal equivalent (e.g., shortness of breath, fatigue, or weakness) either with or without prior coronary revascularization should be based upon the documentation of reasons to suspect that symptoms other than chest discomfort are not due to other organ systems (e.g., dyspnea due to lung disease, fatigue due to anemia), by presentation of clinical data, such as respiratory rate, oximetry, lung exam, etc. (as well as d-dimer, chest CT(A), and/or PFTs, when appropriate), and then incorporated into the evaluation of coronary artery disease as would chest discomfort. Most syncope per se is not an anginal equivalent.

### Abbreviations

ADLs	Activities of daily living
CAD	Coronary artery disease
ECG	Electrocardiogram
FFR	Fractional flow reserve
LBBB	Left bundle-branch block
LVEF	Left ventricular ejection fraction
LVH	Left ventricular hypertrophy
MI	Myocardial infarction
MET	Estimated metabolic equivalent of exercise

MPI	Myocardial perfusion imaging
PFT	Pulmonary function test
PVCs	Premature ventricular contractions
SE	Stress echocardiography
VT	Ventricular tachycardia
VF	Ventricular fibrillation
WPW	Wolf Parkinson White

## Policy History

Date	Summary
March 2021	<ul style="list-style-type: none"> <li>• <u>Added annual indication for IC antiarrhythmics</u></li> <li>• <u>Added History of diabetes mellitus, &gt; 40 years old, with calcium score &gt;400</u></li> </ul>
<u>March 2020</u>	<ul style="list-style-type: none"> <li>• <u>Added general information section as Introduction which outlines requirements for documentation of pertinent office notes by a licensed clinician, and inclusion of laboratory testing and relevant imaging results for case review</u></li> <li>• <u>Added clarification of repeat testing in a patient with new or worsening symptoms and negative result at least one year prior to include the statement “AND meets one of the criteria above”</u></li> <li>• <u>Added clarification of frequent PVCs under ventricular arrhythmias which states defined as greater than or equal to 30/hour to include “on remote monitoring”</u></li> <li>• <u>Edited indication of planning for solid organ transplantation to remove the requirement of limited functional capacity but maintaining requirement of ≥ 3 listed risk factors</u></li> <li>• <u>Edits to the Background section include the following:</u> <ul style="list-style-type: none"> <li>○ <u>Indication changed to read as follows: PET is indicated when all the criteria for MPI are met AND There is likely to be equivocal imaging results because of BMI or large breasts or implants or prior thoracic surgery or results of a prior MPI</u></li> </ul> </li> <li>• <u>Removed the statement regarding radiation burden</u></li> <li>• <u>Added edits to the Coronary Artery disease definition section</u></li> <li>• <u>Updated and added new references</u></li> </ul>
<u>November 2019</u>	<ul style="list-style-type: none"> <li>• <u>Removed CPT code +0482T and replaced with code +78434</u></li> </ul>
<u>August 2019</u>	<ul style="list-style-type: none"> <li>• <u>Changes in CAD indications in line with MPI/SE</u></li> <li>• <u>Added infective endocarditis and aortitis indications</u></li> <li>• <u>Removed cardiac neoplasms and masses indication section</u></li> <li>• <u>Added myocardial viability indications</u></li> </ul>

- |  |  |
|--|--|
|  | <ul style="list-style-type: none"> <li>• <u>Expanded indications for cardiac sarcoidosis as the initial and follow-up study</u></li> </ul> |
|--|--|

#### August 2019

- ~~Changes in CAD indications in line with MPI/SE~~
- ~~Added infective endocarditis and aortitis indications~~
- ~~Removed cardiac neoplasms and masses indication section~~
- ~~Added myocardial viability indications~~
- ~~Expanded indications for cardiac sarcoidosis as the initial and follow-up study~~

#### November 2019

- ~~Removed CPT code +0482T and replaced with code +78434~~

#### March 2020

- ~~Added general information section as Introduction which outlines requirements for documentation of pertinent office notes by a licensed clinician, and inclusion of laboratory testing and relevant imaging results for case review~~
- ~~Added clarification of repeat testing in a patient with new or worsening symptoms and negative result at least one year prior to include the statement “AND meets one of the criteria above”~~
- ~~Added clarification of frequent PVCs under ventricular arrhythmias which states defined as greater than or equal to 30/hour to include “on remote monitoring”~~
- ~~Edited indication of planning for solid organ transplantation to remove the requirement of limited functional capacity but maintaining requirement of  $\geq 3$  listed risk factors~~
- ~~Edits to the Background section include the following:~~
  - ~~Indication changed to read as follows: PET is indicated when all the criteria for MPI are met AND There is likely to be equivocal imaging results because of BMI or large breasts or implants or prior thoracic surgery or results of a prior MPI~~
- ~~Removed the statement regarding radiation burden~~
- ~~Added edits to the Coronary Artery disease definition section~~
- ~~Updated and added new references~~

~~March 2021.~~

~~— Added annual indication for IC antiarrhythmics~~

~~— History of diabetes mellitus, > 40 years old, with calcium score >40~~

## REFERENCES

Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for management of patients with ventricular Arrhythmias and the prevention of sudden cardiac death. *J Am Coll Cardiol*. 2018 Oct 2; 72(14):e91-e220.

Anagnostopoulos C, Harbison M, Kelion A, et al. Procedure guidelines for radionuclide myocardial perfusion imaging. *Heart*. 2004; 90:i1-i10. Available at:  
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1876307/pdf/v090p000i1.pdf>

[Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. \*J Am Coll Cardiol\*. 2019; 74:e177–232.](#)

Bateman TM, Dilsizian V, Beanlands RS, et al. American Society of Nuclear Cardiology and Society of Nuclear Medicine and Molecular Imaging Joint Position Statement on the Clinical Indications for Myocardial Perfusion PET. *J Nucl Med*. 2016; 1-3. Available at  
<http://jnm.snmjournals.org/content/early/2016/08/24/jnumed.116.180448.full.pdf>  
Retrieved May 16, 2018.

Bhave NM, Nienaber CA, Clough RE, et al. Multimodality imaging of thoracic aortic diseases in adults. *J Am Coll Cardiol Cardiovasc Imaging*. 2018; 11(6):903-919.

Birnie DH1, Nery PB2, Ha AC3, Beanlands RS2. Cardiac Sarcoidosis. *J Am Coll Cardiol*. 2016 Jul 26; 68(4):411-21. doi: 10.1016/j.jacc.2016.03.605.

Blankstein R, Waller AH. Evaluation of Known or Suspected Cardiac Sarcoidosis. *Circ Cardiovasc Imaging* 2016; 9:e000867. <http://circep.ahajournals.org/content/5/1/229.full>.

[D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study. \*Circulation\*. 2008; 117:743-753.](#)

[Davies JE, Sen S, Dehbi HM, et al. Use of the instantaneous wave-free ratio or fractional flow reserve in PCI. \*N Engl J Med\*. 2017; 376:1824–34.](#)

Doherty JU, Kort S, Mehran R. et al, ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2017 Appropriate use criteria for multimodality imaging in valvular heart disease: A report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. *J Am Coll Cardiol*. 2017; 70(13):1647-1672.

Fazel R, Dilsizian V, Einstein, AJ, et al. ASNC Information Statement, Strategies for defining an optimal risk-benefit ratio for stress myocardial perfusion SPECT. *J Nucl Cardiol*. Epub 2011 Mar 24; 1-8. Available at:  
<https://www.asnc.org/files/Optimal%20Risk-Benefit%20Ratio%20for%20SPECT.pdf>.

Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *Circulation*. 2012; 126(25):e354-471.

Goff DC, Lloyd-Jones, DM, Bennett G, et al. 2013 ACC/AHA Guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, American Society for Preventive Cardiology, American Society of Hypertension, Association of Black Cardiologists, National Lipid Association, Preventive Cardiovascular Nurses Association, and Women Heart: The National Coalition for Women With Heart Disease. *J Am Coll Cardiol*. 2014; 63(25):2935-2959.

[Götberg M, Christiansen EH, Gudmundsdottir IJ, et al. Instantaneous wave-free ratio versus fractional flow reserve to guide PCI. \*N Engl J Med\*. 2017; 376:1813–23.](#)

[Götberg M, Cook CM, Sen S, et al. The evolving future of instantaneous wave-free ratio and fractional flow reserve. \*J Am Coll Cardiol\*. 2017; 70\(11\):1379-1402.](#)

Grani C, Buechel RR, Kaufmann PA, et al. Multimodality imaging in individuals with anomalous coronary arteries. *J Am Coll Cardiol*. 2017; 10(4):471-581.

Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis; The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). *Eur Heart J*. 2015; 36:3075–3123.

Hendel RC, Berman DS, Di Carli MF, et al. ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009

Appropriate use criteria for cardiac radionuclide imaging: A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine. *J Am Coll Cardiol*. 2009; 53(23):2201-2229.

Hirshfeld JW, Ferrari VA, Bengel FM, et al. 2018 ACC/HRS/NASCI/SCAI/SCCT Expert consensus document on optimal use of ionizing radiation in cardiovascular imaging: Best practices for safety and effectiveness: A report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways Developed in Collaboration with Mended Hearts. *J Am Coll Cardiol*. 2018 June. Available at: <http://www.onlinejacc.org/content/early/2018/04/30/j.jacc.2018.02.016>.

Jaarsma C, Leiner T, Bekkers SC, et al. Diagnostic performance of noninvasive myocardial perfusion imaging using single-photon emission computed tomography, cardiac magnetic resonance, and positron emission tomography imaging for the detection of obstructive coronary artery disease: a meta-analysis, A meta-analysis of 166 articles. *J Am Coll Cardiol*. 2012; 59(19):1719-28.

Lancellotti P, Knomo VT, Badano LP, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: A report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. *Eur Heart J Cardiovasc Imaging*. 2013; 14:721–740.

Lentine KL, Costa SP, Weir MR. Cardiac disease evaluation and management among kidney and liver transplantation candidates. *J Am Coll Cardiol*. 2012; 60(5):434-480.

Lotfi A, Davies JE, Fearon WF, Grines CL, Kern MJ, Klein LW. Focused update of expert consensus statement: Use of invasive assessments of coronary physiology and structure: A position statement of the society of cardiac angiography and interventions. *Catheter Cardiovasc Interv*. 2018 Jul 3.

Mark DB, Hlatky MA, Harrell FE Jr, Lee KL, Califf RM, Pryor DB. (1987) Exercise treadmill score for predicting prognosis in coronary artery disease. *Ann Intern Med*; 106(6):793-800.

McArdle BA, Dowsley TF, deKemp RA, et al. Does rubidium-82 have superior accuracy to SPECT perfusion imaging for the diagnosis of obstructive coronary disease? A systematic review and meta-analysis. *J Am Coll Cardiol*. 2012; 60:1828–1837. Available at: <https://www.sciencedirect.com/science/article/pii/S0735109712030471?via%3Dihub>.

[McClelland RL, Jorgensen NW, Budoff M, et al. 10-year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors: Derivation in the MESA \(Multi-](#)

[Ethnic Study of Atherosclerosis\) with validation in the HNR \(Heinz Nixdorf Recall\) Study and the DHS \(Dallas Heart Study\). JACC. 2015; 66\(15\):1643-53.](#)

McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A scientific statement for health professionals From the American Heart Association. *Circulation*. 2017; 135(17):e927.

Montalescot G, Sechtem U, Achenbach S., et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J*. 2013; 34(38):2949–3003. Available at: <https://academic.oup.com/eurheartj/article/34/38/2949/442952>.

Osborne MT, Hulte EA, Singh A, et al. Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. *J Nucl Cardiol*. 2014; 21(1):166-174.

Parker MW, Iskandar A, Limone B, et al. Diagnostic accuracy of cardiac positron emission tomography versus single photon emission computed tomography for coronary artery disease: A bivariate meta-analysis. *Circ Cardiovascular Imaging*. 2012; 5:700–707.

Patel MR, Bailey SR, Bonow RO, et al. ACCF/SCAI/AATS/AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS Appropriate use criteria for diagnostic catheterization: A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. *JACC*. 2012; 59(22):1995-2027.

Patel MR, Calhoon JH, Dehmer GJ, et al. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate use criteria for coronary revascularization in patients with stable ischemic heart disease. *J Am Coll Cardiol*. 2017; 69(17):2212-2241.

Patel MR, White RD, Abbara S, et al. ACCF/ACR/ASE/ASNC/SCCT/SCMR Appropriate utilization of cardiovascular imaging in heart failure: A joint report of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Foundation Appropriate Use Criteria Task Force. *J Am Coll Cardiol*. 2013; 61(21):2207-2231.

Rahbar K, Seifarth H, Schäfers M, et al. Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT. *J Nucl Med*. 2012; 53(6):856-63.



[Reiffel JA, Camm AJ, Belardinelli L, et al. The HARMONY Trial: Combined ranolazine and dronedarone in the management of paroxysmal atrial fibrillation: Mechanistic and therapeutic synergism. \*Circ Arrhythm Electrophysiol\*. 2015; 8\(5\):1048.](#)

[Ridker PM, Buring JE, Rifai N, et al. NIH Estimate of 10 Year coronary artery disease risk from Framingham Risk Score: Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. \*JAMA\*. 2007; 297\(6\):611-619. Available at: <http://jama.jamanetwork.com/article.aspx?articleid=205528>.](#)

Salaun E, Habib G. Beyond standard echocardiography in infective endocarditis: computed tomography, 3-dimensional imaging, and multi-imaging. *Circ Cardiovasc Imaging*. 2018; 11(3):1-4. Available at: <http://circimaging.ahajournals.org/content/11/3/e007626>

Schindler, TH, Schelbert, HR, Quercioli, A, et al. Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health. *J Am Coll Cardiol Imaging*. 2010; 3(6):623-640.

[Shen W, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS Guideline for the evaluation and management of patients with syncope: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. \*J Am Coll Cardiol\*. 2017;70\(5\): 620-663.](#)

[Sorajja P, Iskandrian A, Tarantini G. Myocardial bridging of the coronary arteries. UpToDate. Published July 2021. Accessed August 13, 2021. <https://www.uptodate.com/contents/myocardial-bridging-of-the-coronary-arteries>.](#)

Tsai JP, Yun CH, Wu TH, et al. A meta-analysis comparing SPECT with PET for the assessment of myocardial viability in patients with coronary artery disease. *Nucl Med Commun*. 2014; 35(9):947-54.

Vita T, Okada DR, Veillet-Chowdhury M, et al. Complementary value of cardiac magnetic resonance imaging and positron emission tomography/computed tomography in the assessment of cardiac sarcoidosis. *Circ Cardiovas Imaging*. 2018; 11(1):e007030. Available at: <http://circimaging.ahajournals.org/content/11/1/e007030>

Wang A, Gaca JG, Chu VH. Management consideration in infective endocarditis: A review. *NEJM*. 2018; 320(1):72-83.

Wolk MJ, Bailey SR, Doherty JU, et al. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 Multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular

Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. *J Am Coll Cardiol*. 2014; 63(4):380-406. Available at: <http://content.onlinejacc.org/article.aspx?articleid=1789799>.

Yancy C, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013; 62(16):e147-237.

Reviewed / Approved by NIA Clinical Guideline Committee

*Rosalind C. Watman D.O.*

~~Rosalind C. Watman, D.O., Medical Director, Cardiology~~

**Disclaimer:** Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates ("Magellan"). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.